Research Topics
Species | Stanley FahnSummaryAffiliation: Columbia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Description of Parkinson's disease as a clinical syndromeStanley Fahn
Department of Neurology, Columbia University College of Physicians Surgeons, New York, New York 10032, USA
Ann N Y Acad Sci 991:1-14. 2003..Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found...- Neurodegeneration and neuroprotection in Parkinson diseaseStanley Fahn
Department of Neurology, Columbia University, New York, New York 10032, USA
NeuroRx 1:139-54. 2004..We then outline potential approaches to neuroprotection for PD that are derived from current notions on disease pathogenesis... - Levodopa and the progression of Parkinson's diseaseStanley Fahn
Columbia University, New York, USA
N Engl J Med 351:2498-508. 2004..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease... - How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?Stanley Fahn
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
Ann Neurol 64:S56-64. 2008..There is thus a need for experienced and knowledgeable physicians and surgeons who are able to handle these motor complications. This review discusses available medications and surgical approaches, and their outcomes... - The history of dopamine and levodopa in the treatment of Parkinson's diseaseStanley Fahn
Columbia University, New York, USA
Mov Disord 23:S497-508. 2008..Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases... - Does levodopa slow or hasten the rate of progression of Parkinson's disease?Stanley Fahn
Neurological Institute, Columbia University College of Physicians and Surgeons, 710 West 168th Street, New York, NY 10032, USA
J Neurol 252:IV37-IV42. 2005..Levodopa's toxicity to neurons in vitro has raised concerns if it might hasten the progression of PD, although in vivo animal studies suggest it may be neuroprotective... - Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort methodYuanjia Wang
Department of Biostatistics, Mailman School of Public Health, New York, New York, USA
Arch Neurol 65:467-74. 2008..To estimate the risk of Parkinson disease (PD) in individuals with mutations in the Parkin gene... - Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease studyKaren S Marder
Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 W 168th St, Unit 16, New York, NY 10032, USA
Arch Neurol 67:731-8. 2010..Mutations in the parkin gene are the most common genetic cause of early-onset Parkinson disease (PD). Results from a multicenter study of patients with PD systematically sampled by age at onset have not been reported to date... - Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD StudyElise Caccappolo
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
J Int Neuropsychol Soc 17:91-100. 2011..Carriers of parkin mutations, whether or not they have PD, do not perform differently on neuropsychological measures as compared to noncarriers. The cognitive functioning of parkin carriers over time warrants further study... - Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's diseaseRoy N Alcalay
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
J Clin Exp Neuropsychol 32:775-9. 2010..GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations... - Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease studyRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 67:1116-22. 2010..To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling... - Case-control study of the parkin gene in early-onset Parkinson diseaseLorraine N Clark
Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Arch Neurol 63:548-52. 2006..To our knowledge, all previous studies have been restricted to PD cases; this is the first study to systematically screen the parkin coding regions and exon deletions and duplications in controls... - Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish populationXinmin Liu
Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, NY, USA
BMC Med Genet 12:104. 2011..Collectively the associations identified in these GWAS account for only a small proportion of the estimated total heritability of PD suggesting that an 'unknown' component of the genetic architecture of PD remains to be identified... - Association of glucocerebrosidase mutations with dementia with lewy bodiesLorraine N Clark
Taub Institute for Research onAlzheimer s Disease and the Aging Brain, Columbia University, New York, NY 10032, USA
Arch Neurol 66:578-83. 2009..Mutations in the glucocerebrosidase (GBA) gene are associated with Lewy body (LB) disorders... - Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 66:1517-22. 2009.... - A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuationsKaren Blindauer
Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
Arch Neurol 63:210-6. 2006..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration... - Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted... - Rasagiline improves quality of life in patients with early Parkinson's diseaseKevin M Biglan
Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
Mov Disord 21:616-23. 2006..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline... - Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear... - Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida
Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
Mov Disord 21:1716-21. 2006..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction... - Contribution of aging to the severity of different motor signs in Parkinson diseaseGilberto Levy
Statistical Analysis Center, Department of Biostatistics, Columbia University, New York, NY 10032, USA
Arch Neurol 62:467-72. 2005..This knowledge may have implications for clinical trials of neuroprotective agents in PD... - Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin geneLorraine N Clark
Department of Pathology, Columbia University, New York, New York 10032, USA
Mov Disord 22:932-7. 2007..Here, we show the utility of a genotyping array for Parkinson's disease by analysis of 60 subjects from the Genetic Epidemiology of Parkinson Disease (GEPD) study that includes 15 early-onset PD case probands and 45 relatives... - A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank
Department of Neurology, Boston University School of Medicine, Boston, MA, USA
Clin Neuropharmacol 31:127-33. 2008..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal... - Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participantsK Marder
Departments of Neurology and Psychiatry, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Gertrude H Sergievsky Center, Columbia University, New York, NY 10032, USA
Neurology 73:385-92. 2009..To examine caloric intake, dietary composition, and body mass index (BMI) in participants in the Prospective Huntington At Risk Observational Study (PHAROS)... - Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicityLorraine N Clark
Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University, New York, New York, USA
Mov Disord 20:100-3. 2005..4, P = 0.2). A total of 17 PD cases carry the N370S allele, including 2 homozygotes and 15 heterozygotes. The N370S allele (nt.1226 A>G) may be associated with PD in patients of Jewish ethnicity and should be examined in a larger study... - ALS lessons learned from other neurological diseases. Parkinson's diseaseStanley Fahn
Columbia University, New York, New York, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:26-30. 2004 - Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysisChris C Tang
Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, NY, USA
Lancet Neurol 9:149-58. 2010..We aimed to assess whether metabolic brain imaging combined with spatial covariance analysis could accurately discriminate patients with parkinsonism who had different underlying disorders... - Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutationMelissa J Nirenberg
Division of Movement Disorders, Department of Neurology, Weill Cornell Medical College, New York, New York 10021, USA
Mov Disord 22:251-4. 2007..These findings suggest that abnormal expansion of the SCA3 gene may be a risk factor for the development of MSA-C... - Status of fetal tissue transplantation for the treatment of advanced Parkinson diseasePaul E Greene
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA
Neurosurg Focus 13:e3. 2002..The authors believe that these problems must be solved before fetal tissue transplantation can be considered a therapeutic option for PD... - Fatigue in levodopa-naive subjects with Parkinson diseaseG Schifitto
University of Rochester, NY, USA
Neurology 71:481-5. 2008..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial... - A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data... - Familial aggregation of early- and late-onset Parkinson's diseaseKaren Marder
Department of Neurology, Columbia University, New York, NY, USA
Ann Neurol 54:507-13. 2003..Genetic factors are important in both early- and late-onset PD, but specific genes and mode of inheritance may differ between the two groups... - Diagnosing Parkinson's disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnosesElan D Louis
The Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
Mov Disord 17:513-7. 2002..A limitation is that patients with milder PD of shorter duration may not be recognized as PD... - Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutationsLorraine N Clark
Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University, New York, New York, USA
Mov Disord 19:796-800. 2004..Mutations in the DJ-1 gene are rare in EOPD in both sporadic and familial cases... - Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexesPaul H Gordon
Department of Neurology, Division of Movement Disorders, Columbia-Presbyterian Medical Center, New York, New York 10032, USA
Mov Disord 19:950-61. 2004..A woman who had her first serious fall at age 48 years subsequently developed neurological symptoms. Her case is described, differential diagnoses are presented, pathology is discussed, and a final diagnosis is reached... - Parkinson's disease: 10 years of progress, 1997-2007Stanley Fahn
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA
Mov Disord 25:S2-14. 2010.... - Treatment issues in psychogenic-neuropsychiatric movement disordersDaniel T Williams
Department of Psychiatry, Columbia University, New York, New York, USA
Adv Neurol 96:350-63. 2005.... - Movement disorders fellowship training program at Columbia University Medical Center in 2001-2002Carlos Portera-Cailliau
Department of Neurology, Columbia University Medical Center, New York, New York, USA
Mov Disord 21:479-85. 2006..Video rounds allow greater exposure to uncommon diagnoses. Similar data from other movement disorder training programs are needed to help create guidelines for formal accreditation and to improve clinical training in this subspecialty... - Reaction time and movement time after embryonic cell implantation in Parkinson diseasePaul H Gordon
Department of Neurology and Clinical Motor Physiology Laboratory, Columbia-Presbyterian Medical Center, New York, NY 10032, USA
Arch Neurol 61:858-61. 2004..These findings support further research into nigral cell implantation for PD... - Lack of familial aggregation of Parkinson disease and Alzheimer diseaseGilberto Levy
Statistical Analysis Center, Department of Biostatistics, Columbia University, 630 W. 168th Street, New York, NY 10032, USA
Arch Neurol 61:1033-9. 2004..CONCLUSION: The lack of familial aggregation of PD and AD does not support the hypothesis of major shared genetic contributions to the etiology of the 2 most common neurodegenerative disorders... - Classification of movement disordersStanley Fahn
Department of Neurology, Columbia University Medical Center, New York, New York, USA
Mov Disord 26:947-57. 2011..First is a review of movement disorders as a group; then, the evolving classifications for 3 of them--parkinsonism, dystonia, and tremor--are covered in detail... - Diagnosis and management of pergolide-induced fibrosisPinky Agarwal
Department of Neurology, Columbia-Presbyterian Medical Center, Division of Movement Disorders, New York, New York, USA
Mov Disord 19:699-704. 2004..Based on our experience with these patients and a review of cases of pergolide-induced fibrosis in the English-language literature, we propose guidelines for the diagnosis and management of this rare complication... - Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromesRebecca M Wolf Gilbert
Department of Neurology, NYU Langone Medical Center, New York, New York 10016, USA
Mov Disord 25:1868-75. 2010..Having MND may be a risk factor for parkinsonism. A prospective study may elucidate this possibility... - Severe cervical dystonia in pathologically proven Parkinson's disease and dementiaOren Cohen
Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA
Mov Disord 18:1381-2. 2003..The clinical diagnosis of Parkinson's disease and dementia (PDD) was confirmed at autopsy... - The early history of paroxysmal dyskinesiasStanley Fahn
Department of Neurology, Columbia University, Columbia-Presbyterian Medical Center, Neurological Institute, New York, New York, USA
Adv Neurol 89:377-85. 2002 - The Unified Myoclonus Rating ScaleSteven J Frucht
Department of Neurology, Columbia University, Columbia-Presbyterian Medical Center, Neurological Institute, New York, New York, USA
Adv Neurol 89:361-76. 2002 - Overview, history, and classification of myoclonusStanley Fahn
Department of Neurology, Columbia University, Columbia-Presbyterian Medical Center, Neurological Institute, New York, New York, USA
Adv Neurol 89:13-7. 2002 - Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson
University of Rochester Medical Center, Rochester, NY 14620, USA
Ann Neurol 51:604-12. 2002.... - Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonismNorman Kock
Ann Neurol 52:257-8; author reply 258. 2002 - Dyskinesia after fetal cell transplantation for parkinsonism: a PET studyYilong Ma
Center for Neurosciences, North Shore Long Island Jewish Research Institute and Department of Neurology, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA
Ann Neurol 52:628-34. 2002..These findings suggest that unbalanced increases in dopaminergic function can complicate the outcome of neuronal transplantation for parkinsonism... - Does personality change as a result of fetal tissue transplantation in the brain?Cynthia McRae
College of Education, University of Denver, Denver, CO 80208, USA
J Neurol 250:282-6. 2003..Results indicate that personality, as measured by the NEO-FFI, basically remained stable during the two-year follow-up period of this study. In this case, no change is regarded as a positive outcome... - Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson diseaseWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
Hypertension 52:587-93. 2008..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet... - Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL... - Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventionsChristopher G Goetz
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 23:690-9. 2008..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials... - Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing planChristopher G Goetz
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
Mov Disord 22:41-7. 2007.... - Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trialCynthia McRae
College of Education, University of Denver, Denver, CO 80208, USA
Arch Gen Psychiatry 61:412-20. 2004..This portion of the study investigated the quality of life (QOL) of participants during the 1 year of double-blind follow-up... - Preoperative response to levodopa is the best predictor of transplant outcomeCurt R Freed
Ann Neurol 55:896; author reply 896-7. 2004 - Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
Arch Neurol 65:716-23. 2008..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD... - Huntington's Disease-like 2 (HDL2) in North America and JapanRussell L Margolis
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Ann Neurol 56:670-4. 2004..0098). The results further support the evidence that the repeat expansion at the chromosome 16q24.3 locus is the direct cause of HDL2 and provide preliminary guidelines for the genetic testing of patients with an HD-like phenotype... - Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiencyYoshiaki Furukawa
Ann Neurol 55:147-8. 2004 - Methylphenidate treats apathy in Parkinson's diseaseAnjan Chatterjee
J Neuropsychiatry Clin Neurosci 14:461-2. 2002 - Benefits and risks of pharmacological treatments for essential tremorKelly E Lyons
University of Kansas Medical Center, Kansas City, Kansas 66160, USA
Drug Saf 26:461-81. 2003..The use of medication and/or surgery can provide adequate tremor control in the majority of the patients... - Deep-brain stimulation extends relief from Parkinson's. Electrodes deep in the brain continue relieving Parkinson's disease symptoms for five yearsStanley Fahn
Health News 10:6-7. 2004